PDCD1 and head and neck squamous cell carcinoma: In advanced cancers, such as head and neck squamous cell carcinoma (HNSCC) and advanced melanoma, only 15%-20% and 33%-44% of the patients, respectively, benefit with pembrolizumab or nivolumab (anti-PD-1) treatment (4, 8, 12–15).